Inozyme Pharma Inc. (INZY) News
Filter INZY News Items
INZY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
INZY News Highlights
- INZY's 30 day story count now stands at 2.
- Over the past 16 days, the trend for INZY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about INZY are DEC and RARE.
Latest INZY News From Around the Web
Below are the latest news stories about INOZYME PHARMA INC that investors may wish to consider to help them evaluate INZY as an investment opportunity.
Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)Key Insights Given the large stake in the stock by institutions, Inozyme Pharma's stock price might be vulnerable to... |
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to a new employee to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as inducement material to the new employee entering into e |
Inozyme Pharma to Participate in Upcoming Investor ConferencesBOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Douglas A. Treco, Ph.D., the Company’s chief executive officer and chairman of the board, will participate at the following investor conferences: The Jefferies London Healthcare Conference. The presentation will |
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 – – Topline data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in first quarter of 2024 – – Cash, cash equivalents, and short-term investments as of September 30, 2023 expected to fund operations into the fourth quarter of 2025 – BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, In |
Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held November 2-5, 2023 in Philadelphia, PA. Details of the presentation are as follows: Title: Role of Plasma Inorgan |
10 Stocks With Huge Catalysts on the WayIn this article, we will take a look at the 10 stocks with huge catalysts on the way. To see more such companies, go directly to 5 Stocks With Huge Catalysts on the Way. The US stock market continues to be in a see-saw mode as investors gauge and digest latest data. The latest jobs […] |
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the UpgradeInozyme Pharma, Inc. (INZY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare ConditionsBOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, highlighted the inclusion of Generalized Arterial Calcification of Infancy (GACI), which is caused by mutations in the ENPP1 or ABCC6 genes, in the Genomic England’s Generation Study. This research initiative, embedded within the UK |
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual MeetingBOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will present three posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada. Details of the presentations are |
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)- Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient reported outcomes (PROs) and functional outcomes - - Improvement in the Global Impression of Change (GIC) observed in all three dose cohorts in ABCC6 Deficiency (PXE) trial - - INZ-701 was generally well tolerated and exhibited a favorable safety and immunogenicity profile in both trials - - Company to host conference call and webcast today at 8:00 a.m. ET - BOSTON, Sept. 26, |